ArticleCell2024
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.
Abstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.The Biochemical journal · 2026Article
- A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodies.Npj viruses · 2026Article
- Genetic diversity of the malaria vaccine candidate PfRIPR in a high transmission region of Senegal.iScience · 2026Article
- Structure-guided design of a PfCyRPA-based vaccine against blood-stage malaria.EMBO molecular medicine · 2026Article
- Erythrocyte invasion in malaria: from molecular mechanisms to rational vaccines.Nature reviews. Microbiology · 2026Review
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.The Journal of experimental medicine · 2025Article
- PfRH5 vaccine; from the bench to the vial.NPJ vaccines · 2025Review
- A strain-transcending anti-AMA1 human monoclonal antibody neutralizes malaria parasites independent of direct RON2L receptor blockade.Cell reports. Medicine · 2025Article
- Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs.Scientific reports · 2025Article
- Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein.Science (New York, N.Y.) · 2025Article
- RH5 antigenic landscape shapes vaccine and antibody development.Trends in pharmacological sciences · 2024Article
- Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.NPJ vaccines · 2024Article
- Intermittent Preventive Treatment of Malaria in Pregnancy and the Impact on Neonates in African Countries as Assessed by Entropy Weight and TOPSIS Methods.Journal of clinical medicine · 2024Article
- Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.The Lancet. Infectious diseases · 2024Article
- Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.Cell reports. Medicine · 2024Article
- Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.Nature communications · 2024Article
- Estimation of PfRh5-based vaccine efficacy in asymptomaticFrontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Jordan R BarrettDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Dimitra PipiniDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Nathan D WrightCentre for Medicines Discovery, University of Oxford, Oxford OX3 7FZ, UK.
Andrew J R CooperAntibody Biology Unit, Laboratory of Immunogenetics, NIAID/NIH, Rockville, MD 20852, USA.
Giacomo GoriniThe Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Doris QuinkertDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Amelia M LiasDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Hannah DaviesDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Cassandra A RigbyDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.
Maya AleshnickVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Barnabas G WilliamsDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
William J BradshawCentre for Medicines Discovery, University of Oxford, Oxford OX3 7FZ, UK.
Neil G PatersonDiamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, Oxfordshire OX11 0DE, UK.
Thomas MartinsonVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Payton KirtleyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Luc PicardDepartment of Biological Engineering, MIT, Cambridge, MA, USA.
Christine D WigginsDepartment of Biological Engineering, MIT, Cambridge, MA, USA.
Francesca R DonnellanDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Lloyd D W KingDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Lawrence T WangDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; Antibody Biology Unit, Laboratory of Immunogenetics, NIAID/NIH, Rockville, MD 20852, USA.
Jonathan F PopplewellCarterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA.
Sarah E SilkDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Jed de Ruiter SwainDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Katherine SkinnerDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Vinayaka KotraiahLeidos Life Sciences, Frederick, MD, USA.
Amy R NoeLeidos Life Sciences, Frederick, MD, USA.
Randall S MacGillCenter for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
C Richter KingCenter for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
Ashley J BirkettCenter for Vaccine Innovation and Access, PATH, Washington, DC 20001, USA.
Lorraine A SoissonUSAID, 1300 Pennsylvania Avenue NW, Washington, DC 20004, USA.
Angela M MinassianDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Douglas A LauffenburgerDepartment of Biological Engineering, MIT, Cambridge, MA, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Carole A LongLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Brandon K WilderVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Lizbé KoekemoerCentre for Medicines Discovery, University of Oxford, Oxford OX3 7FZ, UK.
Joshua TanAntibody Biology Unit, Laboratory of Immunogenetics, NIAID/NIH, Rockville, MD 20852, USA.
Carolyn M NielsenDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Kirsty McHughDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.
Simon J DraperDepartment of Biochemistry, University of Oxford, Oxford OX1 3QU, UK; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: simon.draper@bioch.ox.ac.uk.
Funding
Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6MHuman monoclonal antibodies targeting infectious pathogensZIAAI001260 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TAN, JOSHUA · 2020 to 2025
$10.2MIntramural NIH HHS Z99 AI999999Wellcome Trust
Abstract
The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features of the human vaccine-induced antibody response that confer highly potent inhibition of malaria parasite invasion into red blood cells are not well defined. Here, we characterize 236 human IgG monoclonal antibodies, derived from 15 donors, induced by the most advanced PfRH5 vaccine. We define the antigenic landscape of this molecule and establish that epitope specificity, antibody association rate, and intra-PfRH5 antibody interactions are key determinants of functional anti-parasitic potency. In addition, we identify a germline IgG gene combination that results in an exceptionally potent class of antibody and demonstrate its prophylactic potential to protect against P. falciparum parasite challenge in vivo. This comprehensive dataset provides a framework to guide rational design of next-generation vaccines and prophylactic antibodies to protect against blood-stage malaria.
Indexed as
Antibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GMalaria, FalciparumMalaria VaccinesPlasmodium falciparumProtozoan ProteinsAnimalsCarrier ProteinsEpitopesErythrocytesHumansMiceAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanCarrier ProteinsEpitopesImmunoglobulin GMalaria VaccinesProtozoan ProteinsRH5 protein, Plasmodium falciparumantibodyblood stagemAbmalariamonoclonal antibodyPfRH5Plasmodium falciparumpublic clonotypeRH5vaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.